Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2024; 12(17): 3168-3176
Published online Jun 16, 2024. doi: 10.12998/wjcc.v12.i17.3168
Hemolysis attributed to high dose vitamin C: Two case reports
Shi-Wan Wang, Xiao-Wei Zhang, Jin-Xiu Qu, Yi-Zhong Rao, Shuai Lu, Bing Wang, Jia He, Yuan Zhao, Ben-Qiang Rao
Shi-Wan Wang, Xiao-Wei Zhang, Jin-Xiu Qu, Yi-Zhong Rao, Shuai Lu, Bing Wang, Jia He, Yuan Zhao, Ben-Qiang Rao, Center for Oncology Nutrition and Metabolism, Beijing Shijitan Hospital, Capital Medical University/Key Laboratory of Cancer FSMP for State Market Regulation, Beijing 100038, China
Author contributions: Wang SW and Zhang XW participated in patient treatment and summarized patients’ data; Wang SW summarized the data of literature and wrote the manuscript; Qu JX, Lu S, Wang B, He J, Zhao Y and Rao BQ conducted case discussion and treatment analysis; Rao YZ was involved in the creation of the form; Rao BQ guided the research and applied project fund; and all authors have read and approved the final version to be published.
Supported by The National Natural Science Foundation of China, No. 82074061; The National Key Research and Development Program of China, No. 2022YFC2009600.
Informed consent statement: Both patients and their legal guardians gave verbal consent for the anonymous publication of their conditions, and all care was intended to be curative and not research.
Conflict-of-interest statement: The authors declare that they have no financial or non-financial conflicts of interest that could potentially bias the results or interpretation of their study.
CARE Checklist (2016) statement: The guidelines of the “CARE Checklist – 2016: Information for writing a case report” have been adopted.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ben-Qiang Rao, Doctor, MD, PhD, Chief Doctor, Professor, Surgeon, Center for Oncology Nutrition and Metabolism, Beijing Shijitan Hospital, Capital Medical University/Key Laboratory of Cancer FSMP for State Market Regulation, No. 10 Tieyi Road, Yangfangdian, Haidian District, Beijing 100038, China. raobenqiang@bjsjth.cn
Received: January 24, 2024
Revised: March 4, 2024
Accepted: May 7, 2024
Published online: June 16, 2024
Processing time: 132 Days and 1.2 Hours
Core Tip

Core Tip: Two patients suffered from extremely severe hemolysis after high dose vitamin C treatment (HVCT), and both patients had glucose-6-phosphatase dehydrogenase (G6PD) deficiency. By reviewing the literature and summarizing the findings of available case reports, we conclude for the first time that patients who develop hemolytic anemia after HVCT may have G6PD deficiency, thus G6PD deficiency is an absolute contraindication for HVCT. Our treatment protected the patients from acute kidney injury in the context of extremely severe hemolysis. Our experience may be helpful for the treatment of similar cases.